For the quarter ended March 2024, BioMarin Pharmaceutical (BMRN - Free Report) reported revenue of $648.83 million, up 8.8% over the same period last year. EPS came in at $0.71, compared to $0.60 in the year-ago quarter.
The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $649.75 million. With the consensus EPS estimate being $0.60, the EPS surprise was +18.33%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenues: $637.82 million compared to the $644.39 million average estimate based on 10 analysts. The reported number represents a change of +8.8% year over year.
- Revenues- Royalty and other revenues: $11.02 million versus $10.16 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +10.3% change.
- Revenues- Net Product Revenues- NAGLAZYME: $105.60 million versus the eight-analyst average estimate of $114.01 million. The reported number represents a year-over-year change of -14.2%.
- Revenues- Net Product Revenues- VIMIZIM: $192.60 million versus the eight-analyst average estimate of $183.56 million. The reported number represents a year-over-year change of +1.8%.
- Revenues- Net Product Revenues- PALYNZIQ: $75.70 million versus the eight-analyst average estimate of $77.18 million. The reported number represents a year-over-year change of +21.3%.
- Revenues- Net Product Revenues- VOXZOGO: $152.90 million versus $150.65 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +74.2% change.
- Revenues- Net Product Revenues- KUVAN: $35.90 million versus the eight-analyst average estimate of $32 million. The reported number represents a year-over-year change of -28.9%.
- Revenues- Net Product Revenues- ALDURAZYME: $35.30 million versus $32.79 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +2.6% change.
- Revenues- Net Product Revenues- BRINEURA: $39 million compared to the $42.11 million average estimate based on eight analysts. The reported number represents a change of -0.3% year over year.
- Revenues- Net Product Revenues- ROCTAVIAN: $0.80 million compared to the $5.17 million average estimate based on five analysts.
View all Key Company Metrics for BioMarin here>>>Shares of BioMarin have returned +4.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Highest Returns for Any Asset Class
It’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.
Hurry, Download Special Report – It’s FREE >>
For the quarter ended March 2024, BioMarin Pharmaceutical (BMRN - Free Report) reported revenue of $648.83 million, up 8.8% over the same period last year. EPS came in at $0.71, compared to $0.60 in the year-ago quarter.
The reported revenue represents a surprise of -0.14% over the Zacks Consensus Estimate of $649.75 million. With the consensus EPS estimate being $0.60, the EPS surprise was +18.33%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Net product revenues: $637.82 million compared to the $644.39 million average estimate based on 10 analysts. The reported number represents a change of +8.8% year over year.
- Revenues- Royalty and other revenues: $11.02 million versus $10.16 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +10.3% change.
- Revenues- Net Product Revenues- NAGLAZYME: $105.60 million versus the eight-analyst average estimate of $114.01 million. The reported number represents a year-over-year change of -14.2%.
- Revenues- Net Product Revenues- VIMIZIM: $192.60 million versus the eight-analyst average estimate of $183.56 million. The reported number represents a year-over-year change of +1.8%.
- Revenues- Net Product Revenues- PALYNZIQ: $75.70 million versus the eight-analyst average estimate of $77.18 million. The reported number represents a year-over-year change of +21.3%.
- Revenues- Net Product Revenues- VOXZOGO: $152.90 million versus $150.65 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +74.2% change.
- Revenues- Net Product Revenues- KUVAN: $35.90 million versus the eight-analyst average estimate of $32 million. The reported number represents a year-over-year change of -28.9%.
- Revenues- Net Product Revenues- ALDURAZYME: $35.30 million versus $32.79 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +2.6% change.
- Revenues- Net Product Revenues- BRINEURA: $39 million compared to the $42.11 million average estimate based on eight analysts. The reported number represents a change of -0.3% year over year.
- Revenues- Net Product Revenues- ROCTAVIAN: $0.80 million compared to the $5.17 million average estimate based on five analysts.
View all Key Company Metrics for BioMarin here>>>Shares of BioMarin have returned +4.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Highest Returns for Any Asset Class
It’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.
Hurry, Download Special Report – It’s FREE >>
Get the latest research report on BMRN - FREE